Floatz Rating
B62/100
Confidence
Indicative
Sponsor
ImmVira Pharma Co. Ltd
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05756556CT.gov T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma | — | Suspended | — | — | — |
NCT06229340CT.gov Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations | — | Recruiting | — | — | — |
NCT05768178CT.gov DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | — | Recruiting | — | — | — |
NCT05260684CT.gov Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | — | Completed | — | — | — |
NCT04835805CT.gov A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | — | Active Not Recruiting | — | — | — |
NCT04722575CT.gov Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma | — | Active Not Recruiting | — | — | — |
NCT03430947CT.gov Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT03224208CT.gov Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients | — | Terminated | — | — | — |
NCT03273153CT.gov A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | — | Terminated | — | — | — |
NCT03178851CT.gov Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | — | Completed | — | — | — |
Show 20 more trialsShow fewer
NCT03175432CT.gov Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT03101254CT.gov LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | — | Completed | — | — | — |
NCT03005639CT.gov ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma | — | Withdrawn | — | — | — |
NCT02908672CT.gov A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | — | Completed | — | — | — |
NCT02902029CT.gov Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | — | Completed | — | — | — |
NCT03139513CT.gov A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) | — | Completed | — | — | — |
NCT02721459CT.gov XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT02818023CT.gov Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | — | Terminated | — | — | — |
NCT02537600CT.gov Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis | — | Completed | — | — | — |
NCT02036086CT.gov Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | — | Unknown | — | — | — |
NCT02427893CT.gov Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | — | Withdrawn | — | — | — |
NCT02583516CT.gov Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma | — | Completed | — | — | — |
NCT02303951CT.gov Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | — | Terminated | — | — | — |
NCT01959633CT.gov Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | — | Completed | — | — | — |
NCT01876641CT.gov Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | — | Terminated | — | — | — |
NCT01495988CT.gov Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | — | Terminated | — | — | — |
NCT01813214CT.gov The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | — | Terminated | — | — | — |
NCT01689519CT.gov A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma | — | Completed | — | — | — |
NCT01656642CT.gov A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | — | Completed | — | — | — |
NCT01271803CT.gov A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cobimetinib (this asset) | ImmVira Pharma Co. Ltd | P3 | B · 62 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Cobimetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hematopoietic And Lymphoid System Neoplasm | — | P2/3 | B · 62 |
| Malignant Pancreatic Neoplasm | — | P2 | B · 62 |
| Estrogen-Receptor Positive Breast Cancer | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cobimetinib in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cobimetinib-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →